SPARC and head and neck cancer: The expression levels of SPARC in clinical samples were evaluated in a cDNA array assay which included normal tissues and tissues from grade I to IV head and neck cancer patients, including carcinoma of tonsil, pharynx, oropharynx, etc. Our results revealed that mRNA levels of SPARC in normal tissues are significantly lower than that in cancer.